MAPT and Parkinson disease: In addition to ultra-high sensitivity and specificity, the published results evidenced the high consistencies in measured plasma biomarkers with CSF biomarkers44, plasma Aβ1–42/Aβ1–40 with amyloid PET45, plasma T-Tau with magnetic resonance MRI46, plasma Aβ1–42 xT-Tau, α-synuclein, and TDP-43 with clinical diagnosis of AD, PD and FTD, respectively37,42,47–49.